Flu Vaccines Production Facility

NFOE highly values the 12-year working relationship with GSK Biologicals. We take pride in contributing to the company's success, from the initial project designed for IAF Biovac to the projects for GSK Biologicals in Ste-Foy and Laval, also projects in Wavre, Belgium and Marietta, US.

GSK Biologicals has undertaken an extensive master planning initiative to anticipate future land and infrastructure as well as to develop strategize for campus growth and development.

This effort follows over a decade of construction, upgrades, and expansion projects, reflecting the company's commitment to innovation and progress.

One significant milestone was the 1997 expansion and renovation of the Development and Production Complex. Situated within Quebec City's High Technology Park, this state-of-the-art facility became a focal point for human vaccine research and development, designed to meet rigorous Canadian Bureau of Biologics and American FDA standards. It has specialized manufacturing units, research and development areas, vaccine production and packaging zones, quality control laboratories, administrative offices, and employee facilities.

Another notable phase occurred between 2006 and 2007, involving further expansion and renovation of the Development and Production Complex. The expansion aimed to meet heightened production demands and align with evolving regulatory guidelines. This multi-phase project included enhancements to production spaces, quality control labs, storage areas, and more. The successful coordination of parallel efforts within a demanding schedule marked a significant achievement, further solidifying GSK Biologicals' commitment to excellence.

In 2014, the company embarked on yet another significant renovation endeavor, focusing on accommodating new automated vial and syringe filling and visual inspection lines. This initiative demonstrated GSK's dedication to adopting cutting-edge technology and optimizing production efficiency while ensuring strict adherence to cleanliness and integration within the existing production processes. These collective efforts underscore GSK Biologicals' continuous pursuit of innovation and its leadership role in vaccine research and development.